Sermorelin vs Tesamorelin: How the Two Legally Compoundable GH-Axis Peptides Actually Compare

the GH axis in one page

Growth hormone (GH) gets released in pulses by your pituitary gland, mostly at night during deep sleep. Most of what GH does actually happens through a second hormone, IGF-1, which your liver makes in response to GH. Together, GH and IGF-1 support body composition (keeping lean muscle, burning fat), tissue repair, collagen building, and how deeply you sleep.

GH production peaks in adolescence and declines steadily from about age 25. By 60, most adults produce roughly half the GH they did at 20. That decline is part of what people mean when they say they feel older — slower recovery, less deep sleep, thinner skin, harder to keep muscle on, easier to put fat on.

The GH-axis peptides — peptides that prompt your pituitary to make more GH — are the most direct intervention available. They don't replace your body's system with synthetic hormone (that's what injectable HGH does, with its own risks and legal issues). Instead, they signal the pituitary to release more of its own GH, keeping your body's natural rhythm — GH in bursts, with the normal shut-off signals intact.

Sermorelin and Tesamorelin are both GHRH analogs — synthetic versions of the natural GH-releasing hormone (GHRH) your hypothalamus makes. They work by locking onto the same pituitary docking sites your own GHRH uses, triggering the same response.

sermorelin: the classic GHRH analog

Sermorelin is a 29-amino-acid fragment of natural GHRH. Developed in the 1970s, FDA-approved in the 1990s under the brand name Geref for pediatric growth failure. Geref was eventually pulled from the market — not for safety reasons but for commercial ones (the growth failure market was small and dominated by recombinant HGH).

After Geref's withdrawal, Sermorelin continued to be available through 503A compounding pharmacies. Decades of clinical use have established it as the entry-level GH-axis peptide for anti-aging and longevity protocols. Well-tolerated, inexpensive to compound, produces meaningful but modest effects.

In published protocols. Sermorelin is given as a subcutaneous injection before bed. Daily dosing is standard because Sermorelin's half-life is short — about 12 minutes. Nightly timing rides along with your body's natural GH pulse during early sleep, amplifying the natural rhythm rather than replacing it. Specific dose is determined by the prescribing provider during intake.

What patients notice. Better sleep quality is usually the first and most consistent report — often within the first 2-3 weeks. Improved exercise recovery, slightly better body composition, and an overall sense of feeling "younger" emerge over 8-12 weeks of consistent use.

Limitations. Sermorelin is a relatively mild intervention. Patients expecting dramatic effects often don't get them. It's also a daily injection commitment, which some patients find inconvenient over time. For patients with significant GH deficiency or more aggressive body composition goals, Sermorelin alone may not be enough.

tesamorelin: the FDA-approved heavy hitter

Tesamorelin is a modified GHRH analog — a 44-amino-acid peptide with a structural tweak that stops your body from breaking it down as fast, giving it a longer half-life and a more potent GH-releasing effect than Sermorelin.

Tesamorelin is currently FDA-approved under the brand name Egrifta for a specific indication: reducing the deep belly fat around the organs in HIV-associated lipodystrophy. A narrow approval, but it establishes Tesamorelin as an FDA-approved drug with published clinical trial data on efficacy and safety.

Off-label use by longevity physicians is broader. Tesamorelin's stronger GH-releasing effect and demonstrated visceral fat reduction in trials make it a preferred protocol for patients who want something stronger than Sermorelin, particularly for body composition goals. Compounding pharmacies that work with longevity-focused provider networks have been making it for off-label use for years.

In published protocols. Tesamorelin is given as a daily subcutaneous injection. Same nightly timing as Sermorelin. Specific dose is determined by the prescribing provider during intake.

What patients notice. Effects tend to be more pronounced than Sermorelin and emerge faster. Many patients notice body composition changes (visceral fat reduction, lean mass maintenance) within 6-8 weeks. Sleep and recovery effects are similar in quality but often more noticeable in magnitude.

Cost. Tesamorelin is substantially more expensive than Sermorelin. Monthly cost to patients is typically 2-3x higher, reflecting both higher material cost and the branded origin of the molecule.

head-to-head: which one fits which patient

The practical decision typically hinges on a few factors.

Budget. Sermorelin is the affordable option. Tesamorelin is the premium option. For patients on a tight budget, Sermorelin is usually the right starting point.

Goals. Patients whose primary goal is sleep quality and general GH optimization usually do fine on Sermorelin. Patients whose primary goal is specifically visceral fat reduction often respond better to Tesamorelin's stronger effect — though the difference is one of magnitude, not category. Both peptides hit the same receptor pathway.

Age and baseline GH status. Older patients (55+) with more significant age-related GH decline may benefit more from Tesamorelin's potency. Younger patients (40-55) often do well on Sermorelin.

Prior GH peptide experience. Patients who have been on Sermorelin for 6-12 months and either aren't responding well or want a stronger effect are natural candidates to consider Tesamorelin. Patients brand-new to GH-axis peptides usually start with Sermorelin unless they specifically want the stronger intervention from day one.

Lab response. The objective measure that matters most is IGF-1 level. Both peptides should raise IGF-1 into the upper half of the age-adjusted normal range. If Sermorelin doesn't produce the desired IGF-1 response, Tesamorelin generally will — at the cost of higher monthly spend.

what neither peptide is

Neither Sermorelin nor Tesamorelin is synthetic HGH. This matters both legally and biologically.

Injectable recombinant HGH (brand names like Humatrope, Genotropin, Norditropin) delivers finished hormone directly into your bloodstream, bypassing the pituitary entirely. It produces the largest GH effects, but it also carries the most significant risks (insulin resistance, edema, carpal tunnel, and at sustained high doses, potential concerns about cancer promotion). It's also illegal to prescribe for anti-aging or performance-enhancement purposes in the US — legitimate indications are limited to documented pediatric growth hormone deficiency and adult growth hormone deficiency in patients with documented pituitary failure.

Sermorelin and Tesamorelin are not HGH. They stimulate your body's own GH production, preserving the natural pulse-based release pattern and the body's built-in shut-off signals that keep things from going too far. You can't overdose on these peptides the way you can on HGH because your own pituitary won't release more than it's capable of, regardless of how much signaling peptide is around.

That's also why the effects are more modest than HGH. You're amplifying the system's natural response rather than bypassing it. For most patients, that's the right tradeoff — extending your body's natural GH curve rather than replacing it.

why these are the two GHRH peptides that stayed legal

A common question: why are Sermorelin and Tesamorelin available through legitimate 503A compounding today, when several other peptides in the broader biohacker conversation aren't?

The answer is regulatory. In 2023, the FDA moved a set of peptides to Category 2 on the bulk drug substances list, effectively blocking 503A compounding pharmacies from producing them. In February 2026, the administration announced intent to restore a group of peptides back to Category 1, which would return them to legitimate compounding. As of mid-2026, the formal FDA publication of that reclassification is still pending.

Sermorelin and Tesamorelin weren't affected by the 2023 Category 2 action. Sermorelin has a long FDA history via Geref. Tesamorelin is currently FDA-approved via Egrifta. Both have established compounding pathways the 2023 reclassification didn't touch. That's why they remain the two GH-axis peptides that can be legitimately prescribed through 503A compounding right now.

For more on the underlying regulatory framework, see the current state of peptide legality.

stacking with other longevity interventions

Neither Sermorelin nor Tesamorelin is usually taken in isolation by patients who are serious about longevity optimization. The most common pairings:

NAD+ injectable. The GH axis supports anabolic processes and recovery. NAD+ supports cellular energy and DNA repair. Together they address a broader slice of the aging process.

Testosterone (men or women). Testosterone and GH synergize for muscle maintenance, body composition, and sexual function. The combination is common in longevity protocols for both sexes.

Exercise, especially resistance training. GH peptides alone do not build muscle. Combined with resistance training and adequate protein, they optimize your body's response to the work you're already doing.

Patients who add a GH-axis peptide to an already-optimized base (exercise, sleep, nutrition, stress management) generally see the clearest benefits. Patients who expect the peptide to substitute for the basics tend to be disappointed.

For more on what GH-axis peptides do for body composition specifically, see Sermorelin and body composition: what the 12-week timeline actually looks like. For the visceral-fat-specific use case, see Tesamorelin for visceral fat when your DEXA scan looks wrong.